Vemurafenib

Red

Brand Name(s):Zelboraf

Indication:Melanoma – adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma

Rationale:1,2

Considered:Jan-12

Review Date:Nov-20

Comments:
Drug Safety Update
Vemurafenib (Zelboraf): risk of potentiation of radiation toxicity – full information at: https://www.gov.uk/drug-safety-update/vemurafenib-zelboraf-risk-of-potentiation-of-radiation-toxicity
November 2015
…………………………
NICE guidelines [NG14]
Melanoma: assessment and management – full guidance at: http://www.nice.org.uk/guidance/ng14/resources/melanoma-assessment-and-management-1837271430853
July 2015
…………………………
Vemurafenib is recommended as an option for treating BRAF V600 mutationpositive
unresectable or metastatic melanoma only if the manufacturer
provides vemurafenib with the discount agreed in the patient access scheme.
NICE technology appraisal guidance 269 – December 2012